U.S. markets close in 1 hour 47 minutes

Cyclacel Pharmaceuticals, Inc. (CYCC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3600-0.0200 (-1.45%)
As of 02:10PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.3800
Bid1.3500 x 1100
Ask1.3700 x 2900
Day's Range1.3479 - 1.3800
52 Week Range1.2900 - 7.8400
Avg. Volume136,290
Market Cap13.593M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-2.0470
Earnings DateAug 09, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CYCC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cyclacel Pharmaceuticals, Inc.
    Technical Assessment: Bearish in the Intermediate-TermFollowing April's miserable performance, May isn't shaping up much better, at least so far. The S&P 500 took a 9% drubbing into April, and 14 trading days into the new month the index is off another (almost) 6%. Since its closing peak on January 3 at 4,796.56, the "500" made a minor new low on Thursday and is down 896 points (or 18.7)%. The Nasdaq has declined 29% from its November 2021 closing high, while the Nasdaq 100 is off 28%.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

    - Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Publication Confirming Fadraciclib Suppresses MCL1 and Synergistic Activity with Venetoclax in CLL - - Cash Runway through Mid-2023 - - Conference Call Scheduled for May 11, 2022 at 4:30 pm EDT - BERKELEY HEIGHTS, N.J., May 11, 2022 (GLOBE NEWSWIR

  • GlobeNewswire

    Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results

    BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2022 financial results on Wednesday, May 11, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: US/Canada call: (866) 342-8591 / internationa

  • GlobeNewswire

    Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas

    - CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study -BERKELEY HEIGHTS, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Company’s streamlined, multi-cohort Phase